Last reviewed 2026-04-23 · How we verify

Clarithromycin DST (187.5 mg)

Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Bacterial respiratory tract infections, Helicobacter pylori eradication (as part of combination therapy), Mycobacterial infections (MAC prophylaxis/treatment).

At a glance

Mechanism of action

Clarithromycin binds irreversibly to the bacterial 50S ribosomal subunit, blocking peptide translocation and inhibiting protein synthesis. This bacteriostatic action prevents bacterial growth and replication. The 187.5 mg formulation suggests a pediatric or modified-release preparation of this established macrolide antibiotic.

Approved indications

• Bacterial respiratory tract infections
• Helicobacter pylori eradication (as part of combination therapy)
• Mycobacterial infections (MAC prophylaxis/treatment)

Common side effects

• Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
• Headache
• Taste disturbance
• QT prolongation
• Hepatotoxicity

Key clinical trials

• Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Clarithromycin DST (187.5 mg) CI brief — competitive landscape report
• Clarithromycin DST (187.5 mg) updates RSS · CI watch RSS
• Grünenthal GmbH portfolio CI